Research Article
[Retracted] Effectiveness of GnRH Antagonists and Agonists in Patients with Hormone-Sensitive Prostate Cancer: A Retrospective Study
Table 2
Baseline data of the included patients after propensity score matching.
| Indicators | Antagonist | Agonist | value |
| Cases () | 32 | 32 | | Age (year) | | | 0.883 | TNM stage () | | | 0.617 | T1-T2 | 2 | 2 | | T3-T4 | 7 | 7 | | M1 | 23 | 23 | | Gleason score | | | 0.651 | ≤7 points | 8 | 9 | | >7 points | 24 | 23 | | PSA control rate (%) | | | 0.044 | With abiraterone | 84.38 | 53.13 | | Without abiraterone | 66.67 | 50 | | Median value of PSA baseline level (ng/ml) | 204.85 | 211.82 | 0.864 | Median time to reexamination (day) | 60 | 63 | 0.861 |
|
|